SOLGEN™ — Pharmaceutical-grade soy isoflavones for the menopausal transition
Standardized soy isoflavone extract with the highest concentration of genistin & genistein.
- Evidence in women: >600 women in 14 published clinical studies, across seven physiological systems affected by declining oestrogen.
- A broader scientific programme: 26 studies and reports linked to SOLGEN™, audited one by one against the original text.
- Pharmaceutical-grade documentation: eCTD-DMF available upon request.
- Manufactured at EU-GMP facilities.
- Efficient dosage: 200 mg/day.
DROPSORDRY® — Clinically documented support for female urinary continence
Proprietary combination of CUCURBIDIOL® (standardized Cucurbita pepo, 80–90%) and SOLGEN™ (soy isoflavones, 10–20%) for urinary incontinence in perimenopause.
European clinical study — 82 perimenopausal women, 8 weeks (open-label, results vs. baseline):
- −46% urge incontinence episodes · −52% stress urinary incontinence episodes
- −69% nocturia episodes
- −66% daily panty-liner use
- No adverse events reported
- Efficient dosage: 1 g/day for the first 4 weeks and 500mg/day for the following weeks.
NAUSEASTOP® — Standardized ginger science for nausea and vomiting of pregnancy
Ginger extract (Zingiber officinale, 15:1) standardized in gingerols (≥10% HPLC) and in the 6-gingerol/6-shogaol fraction (>30%) — the molecules responsible for the antiemetic effect, unlike the unstandardized ginger powder used in most published trials.
- Proprietary HPLC identity profile; confirmed absence of methyl-eugenol.
- Non-mutagenic ingredient: negative Ames test, performed batch by batch.
- Aligned with ginger’s position as a first-line non-pharmacological option for nausea and vomiting of pregnancy (category evidence, ACOG framework).
- Efficient dosage: 250 mg/twice daily.
SAFFSERENE® — Naturally crafted for mood balance
Sargol-grade saffron stigma extract (Crocus sativus), standardized to 2% safranal, with crocin and picrocrocin — proprietary HPLC profile.
- Designed for women’s key hormonal windows: the luteal phase (PMS) and the menopausal transition.
- Category evidence: randomized clinical trials on saffron report ~50% reduction in PMS symptom severity.
- Health Canada–approved claim: “Contributes to Normal Psychological Function” (granted to IRIDAFRAN®, the ingredient’s historical research brand, in combination with vitamin C) — the only regulator-approved claim in the portfolio.
- Efficient dosage: 15 mg/twice daily.
NEURASITES® — Standardized Petasites hybridus for migraine management in women
Migraine affects women ~3× more than men — a women’s health issue by epidemiology.
- Own real-world evidence: Lungut et al. 2024 (J. Clin. Med.) — 65 patients, 12 months, reduction in migraine frequency and intensity within a combined nutritional protocol (with magnesium, CoQ10 and vitamin D).
- Category evidence: third-party trials on standardized Petasites extract support reductions in monthly migraine frequency.
- Efficient dosage: 150 mg/day.
- Proprietary HPLC profile.
